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Mesenchymal stem cells (MSCs) are multipotential in vitro, but their endogenous properties are poorly
defined. In this issue of Cell Stem Cell, Park et al. (2012) report that an MSC-like, osteolineage-directed
Mx1+ population generates new osteoblasts at sites of bone damage, suggesting its potential for skeletal
repair and regeneration.Bone marrow stromal cells, or mesen-
chymal stem cells (MSCs), are multipotent
stem cells defined by their ability to differ-
entiate into osteoblasts, chondrocytes,
and adipocytes in vitro. The process of
isolating MSCs is surprisingly simple, as
long as one is not too fussy about minimal
heterogeneity. Although their therapeutic
potential is broadly recognized, our un-
derstanding of how their multipotency is
regulated in vivo is relatively sparse. Out-
standing questions include whether MSC
subsets vary in their capacities to give rise
to differentiated progeny in vivo, and if
they have differential abilities to divide
durably and populate stable niches. In this
issue of Cell Stem Cell, Park et al. use
genetic pulse-chase experiments to define
a myxovirus resistance-1 (Mx1)+ stromal
cell population, which undergoes multi-
lineage differentiation in vitro, but in vivo
specifically gives rise to osteoblasts during
bone homeostasis and regeneration.
Three primary cell types regulate bone
growth during youth, bone remodeling in
adult life, and bone repair in response to
injury. The osteoclast, derived from the
hematopoietic lineage, removes old min-
eral and matrix. The osteoblast, which has
an MSC origin, re-lays bone matrix that it
later mineralizes. This postmitotic osteo-
blast generally buries itself into matrix,
wherein it forms dendritic processes to
transform into a mechanosensitive osteo-
cyte. The processes of directed modeling,
remodeling, and repair all require that oste-
oblasts arrive and function at defined skel-
etal sites (Zaidi, 2007). However, the origin
of these cells, and what precise popula-
tionsorsubpopulationsofMSCs immigrate
to undergo osteoblastic conversion, re-
mains unknown.To study functional properties of bone
lineage cell populations, Park et al.
crossed mice driving inducible Cre re-
combinase from osteoblast lineage pro-
moters with ROSA26 fluorescent reporter
mice. Using in vivo dual-photon imaging
of skull bones, the authors first followed
mature osteoblasts and preosteoblasts
and found that numbers of both osteo-
calcin and osterix expressing labeled cells
declined over time. The authors con-
cluded that neither of these populations
had the ability to self-replicate, and that
new osteoblasts must originate from
a cell population that had not previously
expressed either osteocalcin or osterix.
The authors next followed cells labeled
by expression from the Mx1 promoter,
and found that these cells localized at
sites of bone formation, and, unlike post-
mitotic osteoblasts or progenitors-in-
residence, replicated and labeled most
of the endosteal bone cells (Park et al.,
2012). In vitro, Mx1-induced progenitors
were clonogenic and, at the single-cell
level, had the ability to differentiate
into osteoblasts, chondrocytes, or adipo-
cytes. In vivo, the inducedMx1 population
predominantely gave rise to bone, and,
when transplanted, homed to bone sinu-
soidal vessels where they engrafted. In
a series of functional experiments in injury
models, Park et al. next demonstrate that
both induced and transplanted Mx1 cells
migrate to sites of bone injury, proliferate,
and give rise to osteoblasts. Taken to-
gether, their findings define a regenerative
MSC subset in bone and bone marrow
that is responsive to stress and injury
and is restricted to the osteolineage.
The implication of these findings is that
isolated, actively replicating, lineage-Cell Stem Cellrestricted Mx1+ subpopulations might be
more effective than general MSC harvests
in replacing deficient or abnormal cells.
This would likely obviate problems of
premature cell apoptosis or diversion to
unintended cell lines, making the promise
of bone repair and regeneration using
MSCs much more realistic. While barriers
to such application might still reside
in age-related durability differences of
isolated cells, repair by blood-borne Mx1+
cells of a focal fracture is demonstrated
by Park et al. as proof of principle.
Further challenges include determin-
ing whether there are several fate-
preferred MSC subpopulations (Figure 1),
or whether the vast predilection of Mx1+
cells for bone repair arises from the selec-
tive triggering of one most active path-
way. These remain possibilities, particu-
larly because Park et al. note evidence
of limited adipocytic conversion in vivo.
Furthermore, because bone marrow adi-
posity increases with age, it would be
worth determining which subpopulation
or subpopulations undergo conversion
to the adipocyte lineage, and whether
otherwise committed precursors, includ-
ing osteoblast progenitors, can trans-
differentiate in situ. In contrast, the dem-
onstration that Mx1+ cells did not give
rise to chondrocytes is not entirely
surprising. While at least postnatally,
chondrocytes are presumed to reside
primarily in secondary self-regulating
pools within the growth plate, the demon-
stration by Park et al. of newly arrived
Mx1 chondrocytes at fracture sites is
sufficient evidence for Mx1+ cells not
to be chondrocyte precursors. Notwith-
standing whether other lineage-restricted
MSC subpools exist, which seems likely10, March 2, 2012 ª2012 Elsevier Inc. 233
Figure 1. The Nestin+ Mx1+ MSC Pool Is Largely
Osteolineage Selective, with Limited Adipocytic
Conversion, and Is Able to Home to Distant Sites
Where It Undergoes Osteoblastic Differentiation
This lineage-preferred, self-replicating stable subpopula-
tion holds significant promise for bone repair and regener-
ation. Other similar pools committed to chondrocytic,
fibroblastic, and myocytic lineages may also exist within
the niche.
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the definitive delineation of Mx1+ cell
fate by Park et al. becomes invaluable
in selecting cells for autologous bone
repair, as well as for future cell-based
therapies of generalized skeletal dis-
orders, such as osteogenesis im-
perfecta. In approaching skeletal
diseases in humans, it would be par-
ticularly important to know whether
cells with properties as robust as
thosenoted in youngmice canbe repli-
cated with human MSCs. Clinical
exploitation of the Mx1+ pool will also
depend upon a better understanding
of populations distal to the self-repli-
cating niche, such as CD34+ cells,
which may support cell engraftment
(Khosla et al., 2010).The work here augments seminal work
by others, but also defines new and
provocative directions. We must now
understand the contribution of extrinsic
signals, including neural signals, to the
functionality of the newly identified Mx1+
pool. The authors find that the Mx1+ pop-
ulation overlaps with a quiescent, nestin-
expressing MSC subset reported to
regulate egress of hematopoietic stem
cells (HSCs) when triggered by noradren-
alin (Me´ndez-Ferrer et al., 2010). Like-
wise, ancient glycoprotein hormone
receptors, such as FSH and TSH recep-
tors, have been identified both on MSCs
and ESCs destined to become osteo-
blasts (Baliram et al., 2011; Sun et al.,
2006). Furthermore, as bone marrow is
bathed with TNFa among other cytokines,
it makes it well worth studying whether
these diverse but potent signals can
reprogram Mx1+ MSCs at stages before
irreversible specification occurs (Egea
et al., 2011). If so, this may not only
explain the influence of the bone marrow
microenvironment in determining lineage
commitment in situ, but might also allow
Mx1+ cells to be reprogrammed ex vivo
toward different destinies before autolo-
gous transplant. The flip side is the
permissive potential of dysfunctional234 Cell Stem Cell 10, March 2, 2012 ª2012Mx1+ cells in causing myelodysplastic
disease (Raaijmakers et al., 2010).
Finally, it would be important to
examine how the Mx1+ pool responds to
the potent anabolic agent parathyroid
hormone (PTH), which is currently used
for osteoporosis therapy and is likely to
become a drug to promote fracture heal-
ing. PTH, used intermittently in humans,
builds new bone through an osteoblastic
action. The precise subset of cells upon
which PTH acts has yet to be determined,
although it clearly stimulates the dif-
ferentiation of nestin+ cells within the
niche (Me´ndez-Ferrer et al., 2010). The
identification of a novel self-replicating,
lineage-restricted Mx1+ population begs
the question as to whether the os-
teoinductive action of PTH is exerted
primarily via this subset of the nestin+
MSC pool. Likewise, in light of the known
function of Wnt signaling in self-renewal
within the niche (Fleming et al., 2008), it
will be worth determining whether the
anti-sclerostin antibody, a future anabolic
for osteoporosis and fracture healing,
acts primarily upon this newly identified
pool of Mx1+ osteolineage cells. In
combination with a systemically admin-
istered agent to boost the local anabolic
response, the potential for delivery ofElsevier Inc.Mx1+ cells to sites of bone repair or
regeneration appears exceptional.
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